A photo of Punam Malik.

Director, Cincinnati Comprehensive Sickle Cell Center

Program Leader, Hematology and Gene Therapy Program

Marjory J. Johnson Chair, Gene and Cell Therapy

Professor, UC Department of Pediatrics

513-636-1333

513-636-1330

Board Certified

My Biography & Research

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Sickle Cell and Hemoglobin Disorders

Research Divisions

Experimental Hematology and Cancer Biology, Cancer and Blood Diseases, Hematology



Blog Posts

My Education

MBBS: University of Delhi, New Delhi, India, 1985.

MD: University of Delhi, New Delhi, India, 1989.

MS: University of Maryland, Baltimore, MD, 1991.

Fellowship: Children's Hospital Los Angeles, University of Southern California, 1995.

My Publications

Left atrial dysfunction in sickle cell anemia is associated with diffuse myocardial fibrosis, increased right ventricular pressure and reduced exercise capacity. Alsaied, T; Niss, O; Tretter, JT; Powell, AW; Chin, C; Fleck, RJ; Cnota, JF; Malik, P; Quinn, CT; Nagueh, SM; et al. Scientific Reports. 2020; 10.

Progression of albuminuria in patients with sickle cell anemia: A multicenter, longitudinal study. Niss, O; Lane, A; Asnani, MR; Yee, ME; Raj, A; Creary, S; Fitzhugh, C; Bodas, P; Saraf, SL; Sarnaik, S; et al. Blood Advances. 2020; 4:1501-1511.

Effective hematopoietic stem cell-based gene therapy in a murine model of hereditary pulmonary alveolar proteinosis. Hetzel, M; Lopez-Rodriguez, E; Mucci, A; Ha Nguyen, AH; Suzuki, T; Shima, K; Buchegger, T; Dettmer, S; Rodt, T; Bankstahl, JP; et al. Haematologica: the hematology journal. 2020; 105:1147-1157.

End points for sickle cell disease clinical trials: Renal and cardiopulmonary, cure, and low-resource settings. Farrell, AT; Panepinto, J; Desai, AA; Kassim, AA; Lebensburger, J; Walters, MC; Bauer, DE; Blaylark, RM; DiMichele, DM; Gladwin, MT; et al. Blood Advances. 2019; 3:4002-4020.

CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites. Jayavaradhan, R; Pillis, DM; Goodman, M; Zhang, F; Zhang, Y; Andreassen, PR; Malik, P. Nature Communications. 2019; 10.

Role of the coagulation system in the pathogenesis of sickle cell disease. Nasimuzzaman, M; Malik, P. Blood Advances. 2019; 3:3170-3180.

Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. McGann, PT; Niss, O; Dong, M; Marahatta, A; Howard, TA; Mizuno, T; Lane, A; Kalfa, TA; Malik, P; Quinn, CT; et al. American Journal of Hematology. 2019; 94:871-879.

Abnormal submaximal cardiopulmonary exercise parameters predict impaired peak exercise performance in sickle cell anemia patients. Powell, AW; Alsaied, T; Niss, O; Fleck, RJ; Malik, P; Quinn, CT; Mays, WA; Taylor, MD; Chin, C. Pediatric Blood and Cancer. 2019; 66.

Elimination of the fibrinogen integrin aMb2-binding motif improves renal pathology in mice with sickle cell anemia. Nasimuzzaman, M; Arumugam, PI; Mullins, ES; James, JM; VandenHeuvel, K; Narciso, MG; Shaw, MA; McGraw, S; Aronow, BJ; Malik, P. Blood Advances. 2019; 3:1519-1532.

Therapeutic strategies for sickle cell disease: towards a multi-agent approach. Telen, MJ; Malik, P; Vercellotti, GM. Nature Reviews Drug Discovery. 2019; 18:139-158.